Copyright © 2018 Engine Biosciences Pte. Ltd.  All rights reserved.

Drug Discovery’s
Complexity Problem

Cells in our bodies contain networks of millions of complex, non-linear genetic interactions. Malfunctions in just a small number of genes or pathways can lead to diseases of every kind. The key to discovering and developing effective therapies for patients in need? Determining which genetic interactions underlie their diseases.


Recent scientific and clinical advances have revealed that many of the most debilitating diseases, from cancer to neurodegenerative disorders, result from malfunctions in multiple genes and pathways. Traditional approaches to drug discovery – which rely on serial trial-and-error testing of individual therapies or targets – are too slow and costly to test and map the huge number of genetic interactions that underlie these diseases.

Deciphering Biological Complexity to Unlock Drug Discovery

Combining high-throughput, massively parallel biological experimentation with artificial intelligence
Featured in

Faced with these problems, our team asked a few questions:


What if instead of serial experimentation (“one by one”), we could do massively parallel experimentation (“all at once”)?


What if we had rich datasets on genetic interactions in specific biological (e.g. disease) contexts?


What if we could use these datasets to build cellular maps, which could be probed to build a predictive engine for drug discovery?

Our Approach
Our Novel Network
Biomedicine Platform

Our proprietary and patented technologies bring speed, scalability, and cost advantages to the R&D process.


Our high-throughput biological experimentation technologies reduce the exponentially scaling problem of deciphering biological networks biology analysis into a linearly scaling one.


Our tools for proprietary data generation and artificial intelligence approaches are building a more effective predictive engine for drug discovery and medicine. 


Our technologies can be applied across cell types and disease indications, meaning we can extend our impact to touch millions of lives worldwide.


Accelerating drug discovery: Engine has developed a substantially de-risked platform for drug discovery that provides orders-of-magnitude gains in speed, scalability, and cost.

Developing a systematic, scalable network biomedicine platform: Engine’s artificial intelligence and genetic perturbation platform allows researchers and drug developers to uncover the gene interactions and biological networks underlying diseases faster and more cost-effectively than conventionally, test therapies that specifically target these interactions, and make important analyses and predictions for precision medicine applications.

Tackling a fundamental healthcare problem: We still don’t understand the critical biological drivers for specific disease contexts, and this prevents us from creating targeted therapies for patients in need.

Building a world-class team supported by top investors: Our scientific leadership team sit at the forefront of systems and synthetic biology, genome engineering, and data science.  Collectively we have founded over ten technology and biotech companies which have achieved commercial success and technological breakthroughs, and we are passionate about applying our entrepreneurial experiences to our mission at Engine.  Our investors represent some of the world’s leading investors and domain experts in biotech and deep tech.

Jeffrey Lu

(Co-Founder, CEO, Board Director)

Timothy Lu

M.D., Ph.D. (Co-Founder, Board Director, Co-Chair of Scientific  Advisory Board)

Jim Collins 

Ph.D. (Co-Chair of Scientific Advisory Board)

Hu Li

Ph.D. (Scientific Founder)

Prashant Mali

 Ph.D. (Scientific Founder)

Asha Shekaran

 Ph.D. (Lead Biological Scientist & Platform Leader)

Yogavalli Poobalan

M.S. (Senior Research Officer)

Sadiduddin Edbe Selamat

M.S. (Research Officer)

Daphne Teo

M.S. (Co-Founder, Operations,


Professor Shoucheng Zhang Ph.D. (Board Director)

Leon Chen

Ph.D. (Board Director)

David Epstein

Ph.D. (Advisor)




If you find our science and mission exciting, are keen to work with an innovative biotech start-up in scientific or business roles, and feel that you can be a valuable member of our team, please contact us.


We are currently recruiting molecular biologists, data scientists, and business development experts.

Partners and Collaborators

Our platform accelerates and broadens critical areas of drug discovery, including but not limited to Target Discovery, Drug Repositioning and Repurposing, Pathway/MoA Analysis. We work on collaborative research and development, and we also have a burgeoning pipeline of preclinical assets in numerous disease indications. We are developing these programs internally and with partners.  We are committed to partnering and have an active collaboration with a prominent American Fortune 500 company and leading research institutions.


To learn more about partnering opportunities, please contact us

Press & Media

Engine Biosciences is a venture-backed San Francisco- and Asia-based biotech company pioneering network biomedicine. Our proprietary and patented technologies includes both experimental biology methods for data generation and artificial intelligence algorithms for data analysis and predictions. These technologies, developed through several years of research in MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerate and reduce costs of the R&D process for new medical therapies.

San Francisco 

953 Indiana Street


SanFrancisco, CA



160 Robinson Road

23-02 SBF Center